Hepatocellular carcinoma: therapy and prevention.
暂无分享,去创建一个
[1] N. Gruener,et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. , 2003, Gastroenterology.
[2] V. Mazzaferro,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.
[3] S. Thorgeirsson,et al. Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.
[4] L. Rodrigo,et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis , 2003, Hepatology.
[5] H. Nomura,et al. Short‐term interferon‐alfa therapy for acute hepatitis C: A randomized controlled trial , 2004, Hepatology.
[6] Willis C. Maddrey,et al. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. , 1999, Journal of hepatology.
[7] A. Lok. Prevention of hepatitis B virus-related hepatocellular carcinoma. , 2004, Gastroenterology.
[8] R. Wiesner,et al. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. , 2004, Gastroenterology.
[9] Christian Bréchot,et al. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. , 2004, Gastroenterology.
[10] G. Dodd,et al. Thermal ablation for hepatocellular carcinoma. , 2004, Gastroenterology.
[11] C. Arntzen. Pharmaceutical foodstuffs—oral immunization with transgenic plants , 1998, Nature Medicine.
[12] C. Tiribelli,et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. , 2004, Gastroenterology.
[13] S. Thorgeirsson,et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China , 2002, Hepatology.
[14] Lu-Yu Hwang,et al. Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus , 2002, Hepatology.
[15] Hung-Ming Wang,et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma , 2000, Cancer.
[16] A. Befeler,et al. Hepatocellular carcinoma: diagnosis and treatment. , 2002, Gastroenterology.
[17] H. El‐Serag,et al. Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.
[18] Charles R. Thomas,et al. External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy. , 2004, Gastroenterology.
[19] A. Prince,et al. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. , 1997, Vaccine.
[20] J. Wands,et al. Antibody-directed therapy for human hepatocellular carcinoma. , 2004, Gastroenterology.
[21] A. Liberati,et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] M. Houghton,et al. Intrahepatic Genetic Inoculation of Hepatitis C Virus RNA Confers Cross-Protective Immunity , 2001, Journal of Virology.
[23] G. Gores,et al. Diagnosis and staging of hepatocellular carcinoma. , 2004, Gastroenterology.
[24] M. Ozturk. Genetic Aspects of Hepatocellular Carcinogenesis , 1999, Seminars in liver disease.
[25] K. Chayama,et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer , 2000, Hepatology.
[26] H. Moriwaki,et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. , 1996, Digestion.
[27] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.
[28] J. Bruix,et al. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.
[29] S. Fan,et al. The role and limitation of living donor liver transplantation for hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[30] M. Manns,et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. , 2001, Hepato-gastroenterology.
[31] C. Bartolozzi,et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience , 1997, European Radiology.
[32] P. Waldenberger,et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[33] K. Soo,et al. High‐dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial , 2002, Hepatology.
[34] E. Furth,et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[35] Bernard,et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis? , 1998, Alimentary pharmacology & therapeutics.
[36] A. Tamori,et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis , 2001, The Lancet.
[37] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[38] W. Yeo,et al. Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial , 1999, The Lancet.
[39] Akihiro Matsumoto,et al. Hepatocellular carcinoma: recent trends in Japan. , 2004, Gastroenterology.
[40] L. Coussens,et al. Cancer: An inflammatory link , 2004, Nature.
[41] E. Bergsland. Molecular mechanisms underlying the development of hepatocellular carcinoma. , 2001, Seminars in oncology.
[42] Chien-Jen Chen,et al. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: Multistage hepatocarcinogenesis with multifactorial etiology , 2002, Hepatology.
[43] A. Bisceglie. Screening for Hepatocellular Carcinoma: Being Old is not All Bad , 2004, American Journal of Gastroenterology.
[44] T. Livraghi,et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. , 1995, Radiology.
[45] T. Livraghi,et al. Multimodal image‐guided tailored therapy of early and intermediate hepatocellular carcinoma: Long‐term survival in the experience of a single radiologic referral center , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[46] C. Qian,et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice , 2004, Hepatology.
[47] M. Makuuchi,et al. Results of surgical and nonsurgical treatment for small‐sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan , 2000, Hepatology.
[48] F. Farinati,et al. How should patients with hepatocellular carcinoma be staged? , 2000, Cancer.
[49] R. Jordan,et al. Molecular viral oncology of hepatocellular carcinoma , 2003, Oncogene.
[50] P. Marcellin,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.
[51] Y. Shiratori,et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus—An analysis of 236 consecutive patients with a single lesion , 2000, Hepatology.
[52] H. El‐Serag,et al. Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.
[53] S. Kaneko,et al. Prevention of Hepatocellular Carcinoma Development Associated with Chronic Hepatitis by Anti-Fas Ligand Antibody Therapy , 2002, The Journal of experimental medicine.
[54] Yasuyuki Arakawa,et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.
[55] J. Locker. A new way to look at liver cancer , 2004, Hepatology.
[56] K. Boudjema,et al. Adjuvant intra‐arterial injection of iodine‐131–labeled lipiodol after resection of hepatocellular carcinoma , 2003, Hepatology.
[57] F. Lemonnier,et al. Different hepatitis C virus nonstructural protein 3 (Ns3)‐DNA–expressing vaccines induce in HLA‐A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope , 2001, Hepatology.
[58] Ramon Planas,et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.
[59] S. Mulier,et al. Complications of radiofrequency coagulation of liver tumours , 2002, The British journal of surgery.
[60] M. Houghton,et al. Priming of hepatitis C virus–specific cytotoxic t lymphocytes in mice following portal vein injection of a liver‐specific plasmid DNA , 2000, Hepatology.
[61] H. Hasegawa,et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.
[62] K. McGlynn,et al. The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update , 2003, Annals of Internal Medicine.
[63] S. Emerson,et al. Vaccination of Chimpanzees With Plasmid DNA Encoding the Hepatitis C Virus (HCV) Envelope E2 Protein Modified the Infection After Challenge With Homologous Monoclonal HCV , 2000, Hepatology.
[64] M. Di Stasi,et al. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results , 2001, European Radiology.
[65] M. Schwartz,et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. , 2002, The Lancet. Oncology.
[66] R. Bartenschlager,et al. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. , 2001, Gastroenterology.
[67] J. Bruix,et al. Chemoembolization for hepatocellular carcinoma. , 2004, Gastroenterology.
[68] Yasuo Ohashi,et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.
[69] Carlo Bartolozzi,et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. , 2003, Radiology.
[70] J. Bruix,et al. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. , 2004, Radiology.
[71] L. Mohr,et al. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma. , 2003, Zeitschrift fur Gastroenterologie.
[72] John Wong,et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.
[73] M. Figlerowicz,et al. A plant‐derived edible vaccine against hepatitis B virus , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[74] F. Chisari,et al. Immune Pathogenesis of Hepatocellular Carcinoma , 1998, The Journal of experimental medicine.
[75] M. Schwartz. Liver transplantation for hepatocellular carcinoma. , 2004, Gastroenterology.
[76] Oliver N Keene,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.
[77] H. Kinoshita,et al. Correlation Between Preoperative Serum Concentration of Type IV Collagen 7s Domain and Hepatic Failure Following Resection of Hepatocellular Carcinoma , 2004, Annals of surgery.
[78] J. Slater,et al. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. , 2004, Gastroenterology.
[79] J. Hoofnagle,et al. Optimal therapy of hepatitis C , 2002, Hepatology.
[80] A. Tamori,et al. Effects of Long-Term Postoperative Interferon- Therapy on Intrahepatic Recurrence after Resection of Hepatitis C VirusRelated Hepatocellular Carcinoma , 2001, Annals of Internal Medicine.
[81] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.
[82] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[83] J. Bruix,et al. Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.
[84] W. Caselmann,et al. Intraarterial HCC therapy with I-131-Lipiodol. , 2000, Cancer biotherapy & radiopharmaceuticals.
[85] M. Lai,et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.
[86] T. Honda,et al. Effect of the Dose and Duration of Interferon-Alpha Therapy on the Incidence of Hepatocellular Carcinoma in Noncirrhotic Patients with a Nonsustained Response to Interferon for Chronic Hepatitis C , 2001, Oncology.
[87] G. Everson,et al. Adult-to-adult transplantation of the right hepatic lobe from a living donor. , 2002, The New England journal of medicine.
[88] P. Pedersen,et al. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. , 2002, Cancer research.
[89] Jian-Min Yuan,et al. Environmental factors and risk for hepatocellular carcinoma. , 2004, Gastroenterology.
[90] E. Biondi,et al. Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. , 1996, International journal of oncology.
[91] Francesco Donato,et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.
[92] H. Davis,et al. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. , 1996, Vaccine.
[93] G. Davis. Current therapy for chronic hepatitis C. , 2000, Gastroenterology.
[94] T. Liang,et al. Hepatitis C virus–like particles induce virus‐specific humoral and cellular immune responses in mice , 2001, Hepatology.
[95] J. Bruix,et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[96] E. Heathcote,et al. Prevention of hepatitis C virus-related hepatocellular carcinoma. , 2004, Gastroenterology.
[97] William Lee,et al. Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium , 2000, Annals of Internal Medicine.
[98] J. Bruix,et al. Selection of candidates with HCC for transplantation in the MELD era , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[99] Dexiang Chen,et al. Epidermal Powder Immunization Induces both Cytotoxic T-Lymphocyte and Antibody Responses to Protein Antigens of Influenza and Hepatitis B Viruses , 2001, Journal of Virology.
[100] C. Trautwein,et al. Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.
[101] Michael J Thun,et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.
[102] S. Locarnini,et al. Antiviral chemotherapy for the treatment of hepatitis B virus infections. , 2000, Gastroenterology.
[103] R. Xu,et al. An update on the molecular genetics of hepatocellular carcinoma. , 2004, Seminars in liver disease.
[104] Y. Ben-Neriah,et al. NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.
[105] J. Millis,et al. Transplantation of liver grafts from living donors into adults--too much, too soon. , 2001, The New England journal of medicine.
[106] Josep Fuster,et al. The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[107] J. Bruix,et al. Prognostic prediction and treatment strategy in hepatocellular carcinoma , 2002, Hepatology.
[108] Q. Ye,et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. , 2004, World journal of gastroenterology.
[109] H. Thomas,et al. Increase in primary liver cancer in the UK, 1979–94 , 1997, The Lancet.
[110] M. Manns,et al. Telomeres and telomerase: A dual role in hepatocarcinogenesis , 2004, Hepatology.
[111] A. Valleron,et al. Trends in primary liver cancer , 1998, The Lancet.
[112] G. Gazelle,et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection , 2003, Cancer.
[113] A. Lok,et al. Management of hepatitis B: 2000--summary of a workshop. , 2001, Gastroenterology.
[114] M. Omata,et al. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. , 2004, Gastroenterology.
[115] D. V. van Thiel,et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. , 1998, Hepato-gastroenterology.
[116] Y. Fong,et al. Hepatocellular carcinoma: current surgical management. , 2004, Gastroenterology.
[117] A. Zuckerman,et al. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine , 2001, Hepatology.
[118] K. Eguchi,et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection , 2003, Cancer.
[119] M. Soulen,et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. , 2004, Gastroenterology.
[120] S. Fan,et al. A randomized placebo‐controlled study of long‐acting octreotide for the treatment of advanced hepatocellular carcinoma , 2002, Hepatology.
[121] M. Abecassis,et al. Living donor liver transplantation for hepatocellular carcinoma. , 2004, Gastroenterology.
[122] M. Sata,et al. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan , 2002 .
[123] J. Wands. Prevention of hepatocellular carcinoma. , 2004, The New England journal of medicine.
[124] Y. Matsuzawa,et al. Hepatocellular Carcinoma (hcc) Causes Death in Patients with Cirrhosis and Is One of the Most Prevalent Malignant Tumours Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. a Randomized Controlled Trial , 2022 .
[125] A. Weiner,et al. Vaccination of chimpanzees against infection by the hepatitis C virus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[126] C. Arntzen,et al. Production of hepatitis B surface antigen in transgenic plants for oral immunization , 2000, Nature Biotechnology.
[127] S. Thorgeirsson,et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.
[128] L. Mohr,et al. Gene therapy for malignant liver disease , 2002, Expert opinion on biological therapy.
[129] Chiung-Nien Chen,et al. Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma , 2003, Oncology.
[130] H. Bertani,et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors , 2001, British Journal of Cancer.
[131] L. Butterfield. Immunotherapeutic strategies for hepatocellular carcinoma. , 2004, Gastroenterology.